[
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know",
    "summary": "In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.25, denoting a +2% change from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=25cad2ad9690ed8210f43981e75e3c8129290f98180f62b320da5ef9d32e03b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744235405,
      "headline": "Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know",
      "id": 133844416,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.25, denoting a +2% change from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=25cad2ad9690ed8210f43981e75e3c8129290f98180f62b320da5ef9d32e03b1"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock rises Wednesday, still underperforms market",
    "summary": "Gilead Sciences Inc. stock rises Wednesday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=b7ed9ef19b6e19f54355d85f1008379f9bb49103d1c4aacfe371b252c733d4d2",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744216560,
      "headline": "Gilead Sciences Inc. stock rises Wednesday, still underperforms market",
      "id": 133848126,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock rises Wednesday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=b7ed9ef19b6e19f54355d85f1008379f9bb49103d1c4aacfe371b252c733d4d2"
    }
  },
  {
    "ts": null,
    "headline": "Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?",
    "summary": "Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "url": "https://finnhub.io/api/news?id=6ccbd9a8698c8ec2fe02273c871a85baef5520ad757e10f07363fff9a9ce86df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744215011,
      "headline": "Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?",
      "id": 133844417,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "url": "https://finnhub.io/api/news?id=6ccbd9a8698c8ec2fe02273c871a85baef5520ad757e10f07363fff9a9ce86df"
    }
  },
  {
    "ts": null,
    "headline": "Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out",
    "summary": "Explore the impact of proposed Pharma tariffs on global markets as major stocks tumble. Click for my updated look at selected picks in the health industry.",
    "url": "https://finnhub.io/api/news?id=d8c8bdc63573f8d0446b53adc6c660707a5a38387c201d6d905b0dc1c387ec40",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744214397,
      "headline": "Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out",
      "id": 133838600,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2046288144/image_2046288144.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Explore the impact of proposed Pharma tariffs on global markets as major stocks tumble. Click for my updated look at selected picks in the health industry.",
      "url": "https://finnhub.io/api/news?id=d8c8bdc63573f8d0446b53adc6c660707a5a38387c201d6d905b0dc1c387ec40"
    }
  },
  {
    "ts": null,
    "headline": "Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1",
    "summary": "ClearBridge Investments, an investment management company, released its “ClearBridge Value Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the strategy underperformed its Russell 1000 Value benchmark, driven by detractors in the energy and financials, which overcame contributions from overweight to energy and underweight to […]",
    "url": "https://finnhub.io/api/news?id=89395c7ea4d7739b2e02f6fbdb38261e68e29367245b0ca3cfbacc6f98e50fa3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744203016,
      "headline": "Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1",
      "id": 133828459,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "ClearBridge Investments, an investment management company, released its “ClearBridge Value Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the strategy underperformed its Russell 1000 Value benchmark, driven by detractors in the energy and financials, which overcame contributions from overweight to energy and underweight to […]",
      "url": "https://finnhub.io/api/news?id=89395c7ea4d7739b2e02f6fbdb38261e68e29367245b0ca3cfbacc6f98e50fa3"
    }
  },
  {
    "ts": null,
    "headline": "2 Top Dividend Stocks That Could Set You Up for Life",
    "summary": "With equity markets in shambles due to President Donald Trump's trade policies, now might be as good a time as any to invest in excellent dividend stocks.  With that said, let's consider two top dividend stocks that should navigate the current storm relatively well and continue performing long after: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD).  AbbVie went public in 2013, splitting from its former parent company, Abbott Laboratories.",
    "url": "https://finnhub.io/api/news?id=8484a7ed54c85626c0a522e21a812859e2b6ee2a2973cf63e94d62c6728cb33d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744196400,
      "headline": "2 Top Dividend Stocks That Could Set You Up for Life",
      "id": 133828318,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "With equity markets in shambles due to President Donald Trump's trade policies, now might be as good a time as any to invest in excellent dividend stocks.  With that said, let's consider two top dividend stocks that should navigate the current storm relatively well and continue performing long after: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD).  AbbVie went public in 2013, splitting from its former parent company, Abbott Laboratories.",
      "url": "https://finnhub.io/api/news?id=8484a7ed54c85626c0a522e21a812859e2b6ee2a2973cf63e94d62c6728cb33d"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Value Strategy Q1 2025 Commentary",
    "summary": "ClearBridge Value Strategy Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=35535e3cea80b09456684a0cb073c03b1717d2f8f368e5df3aa2bd24396ed4a2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744182000,
      "headline": "ClearBridge Value Strategy Q1 2025 Commentary",
      "id": 133826903,
      "image": "",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=35535e3cea80b09456684a0cb073c03b1717d2f8f368e5df3aa2bd24396ed4a2"
    }
  }
]